Eyebright Medical Technology(Beijing) Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Aibo Nord (Beijing) Medical Technology Co., Ltd., a listed enterprise on the Science and Technology Innovation Board (stock abbreviation: "Aibo Medical", stock code: 688050), is located in the Zhongguancun National Independent Innovation Demonstration Zone in Beijing. It is a national high-tech enterprise and a national specialized and innovative "small giant" enterprise. The company focuses on the independent research and development, production, sales, and related services of ophthalmic medical devices. At present, the company's main products cover the fields of surgery and optometry, mainly targeting the main ophthalmic diseases that cause blindness and visual impairment, such as cataracts and refractive errors. The core product in the surgery field is artificial lenses, while the core product in the optometry field is corneal shaping lenses, as well as a series of supporting products developed and produced around these two core products. At the same time, the holding subsidiary of the company has obtained three product registration certificates of color soft contact lenses ("color pupil"), and will continue to invest in the research, development and production of high-end ophthalmic medical devices such as phakic intraocular lens (PR), silicone hydrogel soft contact lenses. The company is innovation oriented, with strong research and development capabilities, and a sound scientific research management system and innovation incentive mechanism. The company owns the "Ophthalmic Biomaterials and Diagnosis and Treatment Technology" Beijing Engineering Laboratory and is a cooperative unit of the "National Ophthalmic Diagnosis and Treatment Equipment Engineering Technology Center". It has undertaken multiple national and Beijing municipal level scientific research projects such as the National Key R&D Plan, the National Torch Plan, and the Innovation Fund of the Ministry of Science and Technology. The company adheres to the business philosophy of "innovation driven, quality driven survival", with the goal of developing a full range of ophthalmic medical products, becoming a leading innovation enterprise in the domestic ophthalmic medical field, and representing "Made in China" Xinli as one of the international advanced medical enterprises. |
| Headquarter | Beijing |
| Establish Date | 4/21/2010 |
| Listed Code | 688050.SH |
| Listed Date | 7/29/2020 |
| Chairman | Jiejiang Ice. |
| CEO | Jiejiang Ice. |
| Website | www.ebmedical.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
